Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Body language expert reveals the one thing keeping Queen Mary and King Frederik togetherKhloe Kardashian takes True and Tatum to see dad Tristan Thompson play for the FIRST TIMELucky Mariners fan ends up with two foul balls on consecutive pitchesUS downhill skier Breezy Johnson banned for 14 months for breaking antiHarry Dunn, former US Capitol police officer, running in competitive Maryland congressional primaryChris Pratt divides fans as he publicly snubs exGolden State's WNBA expansion franchise to be known as the ValkyriesProtesters in PakistanGeorgian parliament holds third and final reading of divisive bill on foreign influenceAnya Taylor
2.3962s , 6605.4296875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Grid news portal